Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't to Introduce Medical Institution Selection System
July 5, 2010
- Explanations on Class 1 OTC Drugs Provided in Writing in Only 50% of Cases: Korosho Survey
July 5, 2010
- Subcommittee Restart Discussions for FY2012 NHI Pricing System Reform
July 5, 2010
- Vorinostat Designated as Orphan Drug
July 5, 2010
- Big J Pharmas Still Reel Them in
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
July 5, 2010
- Add'l Indication for Herceptin Granted Priority Review Status
July 5, 2010
- Tests for Hepatitis Virus Recommended for Tisseel, Gammagard
July 5, 2010
- Remicade Approved for Ulcerative Colitis
July 5, 2010
- 4 Advanced Therapies to Be Approved for Use in Combination with Insurance-Covered Treatments
July 5, 2010
- Amaryl Approved for Pediatric Type 2 Diabetes
July 5, 2010
- Only 50% of Small Hospitals Treat Stroke with t-PA: Pfizer
July 5, 2010
- Eribulin Granted Priority Review Status in Japan
July 5, 2010
- Takeda Launches Actos + Extended-Release Metformin Combination
July 5, 2010
- Easy-Going Deregulation Not Recommendable: Prof. Saruta
July 5, 2010
- Yakult Launches Water Soluble Formulations of Elplat
July 5, 2010
- Kowa Launches Livalo in the US
July 5, 2010
- 5 NHI Price-Related Issues Included in Discussion Agenda
July 5, 2010
- JPMA's PDSC to Subsidize Development of More Unapproved Drugs
July 5, 2010
- ON THE MOVE
July 5, 2010
- Makers Should Not Take Advantage of New Premium to Increase Their Sales Prices: Mr Isobe
July 5, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…